AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly ...

AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.

“We sit in the low 60s in terms of Botox share, and that's a clear leadership position by a large margin in the U.S.,” AbbVie ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.

Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

Healthcare stocks have lagged the broader market for the past three years, weighed down by post-COVID earnings volatility, ...

Scotiabank analyst Louise Chen maintained a Buy rating on AbbVie today and set a price target of $280.00. Chen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Vertex ...

AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its ...

AbbVie is seeking European approval of expanded use of its migraine drug atogepant in adults following strong results from a ...

Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of ...

NANTES, France, December 8th, 2025 - 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced ...